These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32407112)

  • 1. Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B.
    Mackman RL; Mish M; Chin G; Perry JK; Appleby T; Aktoudianakis V; Metobo S; Pyun P; Niu C; Daffis S; Yu H; Zheng J; Villasenor AG; Zablocki J; Chamberlain J; Jin H; Lee G; Suekawa-Pirrone K; Santos R; Delaney WE; Fletcher SP
    J Med Chem; 2020 Sep; 63(18):10188-10203. PubMed ID: 32407112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, pharmacokinetics and pharmacodynamics of selgantolimod, an oral Toll-like receptor 8 agonist: a Phase Ia study in healthy subjects.
    Reyes M; Lutz JD; Lau AH; Gaggar A; Grant EP; Joshi A; Mackman RL; Ling J; Tan SK; Ayithan N; Daffis S; Woo J; Wu P; Lam T; Fletcher SP; Kottilil S; Poonia B; Gane EJ; Mathias A; German P
    Antivir Ther; 2020; 25(3):171-180. PubMed ID: 32667286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Follicular Helper T (T
    Ayithan N; Tang L; Tan SK; Chen D; Wallin JJ; Fletcher SP; Kottilil S; Poonia B
    Front Immunol; 2021; 12():735913. PubMed ID: 34512670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Potential of TLR8 Agonist GS-9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators.
    Amin OE; Colbeck EJ; Daffis S; Khan S; Ramakrishnan D; Pattabiraman D; Chu R; Micolochick Steuer H; Lehar S; Peiser L; Palazzo A; Frey C; Davies J; Javanbakht H; Rosenberg WMC; Fletcher SP; Maini MK; Pallett LJ
    Hepatology; 2021 Jul; 74(1):55-71. PubMed ID: 33368377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral Selective TLR8 Agonist Selgantolimod Induces Multiple Immune Cell Responses in Humans.
    Ayithan N; Ghosh A; Dwivedi A; Wallin JJ; Tan SK; Chen D; Kottilil S; Poonia B
    Viruses; 2021 Nov; 13(12):. PubMed ID: 34960669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toll-Like Receptor 8 Agonist GS-9688 Induces Sustained Efficacy in the Woodchuck Model of Chronic Hepatitis B.
    Daffis S; Balsitis S; Chamberlain J; Zheng J; Santos R; Rowe W; Ramakrishnan D; Pattabiraman D; Spurlock S; Chu R; Kang D; Mish M; Ramirez R; Li L; Li B; Ma S; Hung M; Voitenleitner C; Yon C; Suresh M; Menne S; Cote P; Delaney WE; Mackman R; Fletcher SP
    Hepatology; 2021 Jan; 73(1):53-67. PubMed ID: 32246499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, Pharmacokinetics, and Pharmacodynamics of the Oral TLR8 Agonist Selgantolimod in Chronic Hepatitis B.
    Gane EJ; Kim HJ; Visvanathan K; Kim YJ; Nguyen AH; Wallin JJ; Chen DY; McDonald C; Arora P; Tan SK; Gaggar A; Roberts SK; Lim YS
    Hepatology; 2021 Oct; 74(4):1737-1749. PubMed ID: 33704806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism.
    Niu C; Li L; Daffis S; Lucifora J; Bonnin M; Maadadi S; Salas E; Chu R; Ramos H; Livingston CM; Beran RK; Garg AV; Balsitis S; Durantel D; Zoulim F; Delaney WE; Fletcher SP
    J Hepatol; 2018 May; 68(5):922-931. PubMed ID: 29247725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and Optimization of Pyrrolo[3,2-d]pyrimidine Toll-like Receptor 7 (TLR7) Selective Agonists for the Treatment of Hepatitis B.
    McGowan DC; Herschke F; Pauwels F; Stoops B; Smyej I; Last S; Pieters S; Embrechts W; Khamlichi MD; Thoné T; Van Schoubroeck B; Mostmans W; Wuyts D; Verstappen D; Scholliers A; De Pooter D; Dhuyvetter D; Borghys H; Tuefferd M; Arnoult E; Hong J; Fanning G; Bollekens J; Urmaliya V; Teisman A; Horton H; Jonckers THM; Raboisson P
    J Med Chem; 2017 Jul; 60(14):6137-6151. PubMed ID: 28671847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2,4-Diaminoquinazolines as Dual Toll-like Receptor (TLR) 7/8 Modulators for the Treatment of Hepatitis B Virus.
    Embrechts W; Herschke F; Pauwels F; Stoops B; Last S; Pieters S; Pande V; Pille G; Amssoms K; Smyej I; Dhuyvetter D; Scholliers A; Mostmans W; Van Dijck K; Van Schoubroeck B; Thone T; De Pooter D; Fanning G; Jonckers THM; Horton H; Raboisson P; McGowan D
    J Med Chem; 2018 Jul; 61(14):6236-6246. PubMed ID: 29965759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Pyrimidine Toll-like Receptor 7 and 8 Dual Agonists to Treat Hepatitis B Virus.
    McGowan D; Herschke F; Pauwels F; Stoops B; Last S; Pieters S; Scholliers A; Thoné T; Van Schoubroeck B; De Pooter D; Mostmans W; Khamlichi MD; Embrechts W; Dhuyvetter D; Smyej I; Arnoult E; Demin S; Borghys H; Fanning G; Vlach J; Raboisson P
    J Med Chem; 2016 Sep; 59(17):7936-49. PubMed ID: 27513093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TLR8 agonist partially improves IFN-γ deficiency of NK cells in chronic hepatitis B through the synergy of monocytes.
    Ao X; Gan Q; Huang X; Bao D; Wu X; Lin Q; Lin A; Ding Y; Wang L; Chen Y; Huang Z
    Aliment Pharmacol Ther; 2023 Feb; 57(4):387-398. PubMed ID: 36585909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired expression and function of TLR8 in chronic HBV infection and its association with treatment responses during peg-IFN-α-2a antiviral therapy.
    Deng G; Ge J; Liu C; Pang J; Huang Z; Peng J; Sun J; Hou J; Zhang X
    Clin Res Hepatol Gastroenterol; 2017 Sep; 41(4):386-398. PubMed ID: 28236535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of High-Potency Human TLR8 and Dual TLR7/TLR8 Agonists in Pyrimidine-2,4-diamines.
    Beesu M; Salyer AC; Brush MJ; Trautman KL; Hill JK; David SA
    J Med Chem; 2017 Mar; 60(5):2084-2098. PubMed ID: 28146629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.
    Roethle PA; McFadden RM; Yang H; Hrvatin P; Hui H; Graupe M; Gallagher B; Chao J; Hesselgesser J; Duatschek P; Zheng J; Lu B; Tumas DB; Perry J; Halcomb RL
    J Med Chem; 2013 Sep; 56(18):7324-33. PubMed ID: 23961878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4).
    Ren Q; Liu X; Luo Z; Li J; Wang C; Goldmann S; Zhang J; Zhang Y
    Bioorg Med Chem; 2017 Feb; 25(3):1042-1056. PubMed ID: 28082068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-Based Design of Highly Potent Toll-like Receptor 7/8 Dual Agonists for Cancer Immunotherapy.
    Wang Z; Gao Y; He L; Sun S; Xia T; Hu L; Yao L; Wang L; Li D; Shi H; Liao X
    J Med Chem; 2021 Jun; 64(11):7507-7532. PubMed ID: 34048243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and immunological activities of novel Toll-like receptor 7 and 8 agonists.
    Kandimalla ER; Struthers M; Bett AJ; Wisniewski T; Dubey SA; Jiang W; Precopio M; Sun Z; Wang H; Lan T; Agrawal S; Casimiro DR
    Cell Immunol; 2011; 270(2):126-34. PubMed ID: 21570062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees.
    Lanford RE; Guerra B; Chavez D; Giavedoni L; Hodara VL; Brasky KM; Fosdick A; Frey CR; Zheng J; Wolfgang G; Halcomb RL; Tumas DB
    Gastroenterology; 2013 Jun; 144(7):1508-17, 1517.e1-10. PubMed ID: 23415804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8.
    Lan T; Kandimalla ER; Yu D; Bhagat L; Li Y; Wang D; Zhu F; Tang JX; Putta MR; Cong Y; Trombino AF; Sullivan T; Agrawal S
    Proc Natl Acad Sci U S A; 2007 Aug; 104(34):13750-5. PubMed ID: 17698957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.